Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
4.050
+0.070 (1.76%)
Nov 21, 2024, 11:38 AM EST - Market open
Candel Therapeutics Employees
Candel Therapeutics had 42 employees as of December 31, 2023. The number of employees decreased by 34 or -44.74% compared to the previous year.
Employees
42
Change (1Y)
-34
Growth (1Y)
-44.74%
Revenue / Employee
n/a
Profits / Employee
-$1,242,833
Market Cap
131.53M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 42 | -34 | -44.74% |
Dec 31, 2022 | 76 | 11 | 16.92% |
Dec 31, 2021 | 65 | 24 | 58.54% |
Dec 31, 2020 | 41 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Cibus | 183 |
Zomedica | 144 |
Cabaletta Bio | 103 |
Compugen | 68 |
Cardiff Oncology | 32 |
Avalo Therapeutics | 19 |
Inhibikase Therapeutics | 9 |
Context Therapeutics | 5 |
CADL News
- 16 days ago - Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma - GlobeNewsWire
- 20 days ago - Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think - Seeking Alpha
- 6 weeks ago - Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting - GlobeNewsWire
- 4 months ago - 3 Biotech Names With Potential Catalysts By Year End - Seeking Alpha
- 5 months ago - Candel Therapeutics to Join Russell 3000® Index - GlobeNewsWire
- 6 months ago - FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma - GlobeNewsWire
- 6 months ago - Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting - GlobeNewsWire
- 6 months ago - Candel Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire